Remove DNA Remove Immune Response Remove Manufacturing Remove Protein
article thumbnail

COVID prompts another milestone, as India clears first DNA vaccine

pharmaphorum

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98
article thumbnail

Zydus gets FDA approval for antibiotic drug azithromycin

Pharmaceutical Technology

The approval enables the company to manufacture and market azithromycin to treat infections such as bronchitis, pneumonia and sexually transmitted diseases (STDs). Zydus will manufacture the drug at its formulation facility in Moraiya, Ahmedabad, in the Indian state of Gujarat.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. Related: Red Meat Allergy Test Gets FDA Clearance. “We

article thumbnail

UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials | 2020-12-21

The Pharma Data

SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. In October, Scancell signed a manufacturing deal for SN14 with Cobra Biologics, a Cognate BioServices subsidiary, ahead of a planned phase 1 trial in 2021. Source link.

article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” 74% had measurable cellular responses at the 1.0 mg and 2.0 The 1.0

DNA 40
article thumbnail

Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class

pharmaphorum

Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body. The technology is designed to replace antibodies, which have become standard therapy in many diseases but are complicated and expensive to manufacture.

RNA 98
article thumbnail

Leading innovators in HIV peptides for the pharmaceutical industry

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These can serve as an important component of a vaccine.

Protein 147